Achillion Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small molecule drug therapies for immune system disorders. Its lead drug candidate is ACH-4471, an inhibitor of factor D that is Phase II clinical trials for patients with paroxysmal nocturnal hemoglobinuria (PNH) and C3 glomerulopathy/immune complex membranoproliferative glomerulonephritis. The company is also developing ACH-5228, a factor D inhibitor that is in Phase I clinical trials; and ACH-5548, a factor D inhibitor, which is in Phase I clinical trials for the treatment of PNH and other complement mediated diseases. It has license agreements with Ora, Inc. for the development and commercialization of ACH-702; and GCA Therapeutics, Ltd for elvucitabine, a nucleoside reverse transcriptase inhibitor for the treatment of hepatitis B infection and human immunodeficiency virus infection. The company was founded in 1998 and is based in New Haven, Connecticut.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Phone203-624-7000
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$15 million
Profitability
Miscellaneous
Employees56
Next Earnings Date5/1/2019 (Estimated)
OptionableOptionable
Achillion Pharmaceuticals (NASDAQ:ACHN) Frequently Asked Questions
What is Achillion Pharmaceuticals' stock symbol?
Achillion Pharmaceuticals trades on the NASDAQ under the ticker symbol "ACHN."
How were Achillion Pharmaceuticals' earnings last quarter?
Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) announced its earnings results on Thursday, March, 7th. The biopharmaceutical company reported ($0.12) earnings per share for the quarter, beating analysts' consensus estimates of ($0.15) by $0.03. View Achillion Pharmaceuticals' Earnings History.
When is Achillion Pharmaceuticals' next earnings date?
What price target have analysts set for ACHN?
2 equities research analysts have issued 12-month price targets for Achillion Pharmaceuticals' stock. Their forecasts range from $5.00 to $5.00. On average, they anticipate Achillion Pharmaceuticals' stock price to reach $5.00 in the next year. This suggests a possible upside of 70.6% from the stock's current price. View Analyst Price Targets for Achillion Pharmaceuticals.
What is the consensus analysts' recommendation for Achillion Pharmaceuticals?
2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Achillion Pharmaceuticals in the last year. There are currently 1 hold rating and 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Achillion Pharmaceuticals.
Has Achillion Pharmaceuticals been receiving favorable news coverage?
News stories about ACHN stock have been trending somewhat positive this week, according to InfoTrie Sentiment Analysis. InfoTrie ranks the sentiment of news coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Achillion Pharmaceuticals earned a news impact score of 1.2 on InfoTrie's scale. They also assigned press coverage about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the stock's share price in the immediate future.
Are investors shorting Achillion Pharmaceuticals?
Achillion Pharmaceuticals saw a decline in short interest in the month of March. As of March 15th, there was short interest totalling 12,379,720 shares, a decline of 15.2% from the February 28th total of 14,591,293 shares. Based on an average daily volume of 2,086,359 shares, the short-interest ratio is currently 5.9 days. Approximately 9.2% of the company's stock are short sold. View Achillion Pharmaceuticals' Current Options Chain.
Who are some of Achillion Pharmaceuticals' key competitors?
Some companies that are related to Achillion Pharmaceuticals include Allakos (ALLK), Endo International (ENDP), Zogenix (ZGNX), Mallinckrodt (MNK), Pacira Biosciences (PCRX), Opko Health (OPK), Prestige Consumer Healthcare (PBH), Corcept Therapeutics (CORT), Phibro Animal Health (PAHC), Tricida (TCDA), Innoviva (INVA), Inflarx (IFRX), Myovant Sciences (MYOV), Cambrex (CBM) and Theravance Biopharma (TBPH).
What other stocks do shareholders of Achillion Pharmaceuticals own?
Who are Achillion Pharmaceuticals' key executives?
Achillion Pharmaceuticals' management team includes the folowing people:
- Mr. Joseph Truitt, Pres, CEO & Director (Age 54)
- Ms. Martha E. Manning, Exec. VP, Gen. Counsel & Corp. Sec. (Age 64)
- Mr. Brian R. Di Donato, CFO, SVP & Treasurer (Age 52)
- Mr. Paul Firuta, Exec. VP & COO (Age 53)
- Dr. Kevin P. Malobisky, Sr. VP of Regulatory Affairs, Quality & Compliance
Who are Achillion Pharmaceuticals' major shareholders?
Which major investors are selling Achillion Pharmaceuticals stock?
Which major investors are buying Achillion Pharmaceuticals stock?
How do I buy shares of Achillion Pharmaceuticals?
Shares of ACHN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Achillion Pharmaceuticals' stock price today?
One share of ACHN stock can currently be purchased for approximately $2.93.
How big of a company is Achillion Pharmaceuticals?
Achillion Pharmaceuticals has a market capitalization of $406.45 million and generates $15 million in revenue each year. The biopharmaceutical company earns $-70,270,000.00 in net income (profit) each year or ($0.51) on an earnings per share basis. Achillion Pharmaceuticals employs 56 workers across the globe.
What is Achillion Pharmaceuticals' official website?
How can I contact Achillion Pharmaceuticals?
Achillion Pharmaceuticals' mailing address is 300 GEORGE STREET, NEW HAVEN CT, 06511. The biopharmaceutical company can be reached via phone at 203-624-7000.
MarketBeat Community Rating for Achillion Pharmaceuticals (NASDAQ ACHN)
MarketBeat's community ratings are surveys of what our community members think about Achillion Pharmaceuticals and other stocks. Vote "Outperform" if you believe ACHN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ACHN will underperform the S&P 500 over the long term. You may vote once every thirty days.
